Vectura Group plc provided revenue guidance for the year 2016. Revenues for 2016 are anticipated to be in line with the Board's expectations with positive momentum from the seven key recently-launched inhaled products including flutiform®, Ultibro® Breezhaler®, Seebri® Breezhaler® and the GSK Ellipta® products (Breo®/Relvar® Ellipta®, Anoro® Ellipta® and Incruse® Ellipta®) providing a strong base of recurring revenue.